SLAMF7 and Miyoshi myopathy: We also extended these observations using Elotuzumab, a monoclonal antibody that targets signaling lymphocyte activation molecule family member 7 (SLAMF7/CS1) expressed on the surface of MM and NK cells, and shown to have significant clinical activity in combination therapies for relapsed/refractory MM [46].